Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: A record linkage study

Neurology

Volumn 49, Issue 2, 1997, Pages 542-546

  Tennis, Patricia ^a   Stern, Robert S ^b  

^a GLAXOSMITHKLINE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; PHENYTOIN; VALPROIC ACID;

ANTICONVULSANT THERAPY; ARTICLE; DISEASE COURSE; EPILEPSY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

EID: 0030749007     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.2.542     Document Type: Article

References (14)

1. Roujeau JC, Stern RS. Severe adverse cutaneous reaction to drugs. N Engl J Med 1994;331:1272-1285.
2. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988;82:1826-1832.
3. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-1607.
4. Glaxo Wellcome Inc. Product information for Lamictal (lamotrigine). Research Triangle Park, NC: Glaxo Wellcome Inc., October 1995.
5. Strand LM, Downey W. Health databases in Saskatchewan. In: Strom BL, ed. Pharmacoepidemiology. New York: John Wiley & Sons, 1994:217-230.
6. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: John Wiley & Sons, 1981.
7. Gennis MA, Vermuri R, Burns EA, Hill JV, Miller MA, Spiel-berg SP. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991;91:631-634.
8. Gaedigk A, Spielberg SP, Grant DM. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994;4:142-153.
9. Mockenhaupt M, Rzany B, Baur S, et al. Drug risk for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): evaluation of antiepileptics based on sale numbers in defined daily doses (DDD) [abstract]. Pharmacoepidemiol Drug Safety 1994;3(suppl 1):22.
10. Roujeau JD, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome incidence and drug etiology in France 1981-1985). Arch Dermatol 1990;126:37-42.
11. Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991;127:839-842.
12. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43-47.
13. Askmark H, Wiholm B. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 1990;81:131-140.
14. Delattre JY, Safai B, Posner JB. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 1988;38:194-198.